Form 4: Apellis Pharmaceuticals CFO Timothy Sullivan Executes Stock Options and Sells Shares Under 10b5-1 Plan

Timothy Sullivan, CFO of Apellis Pharmaceuticals, exercised stock options and sold shares of common stock according to a pre-arranged 10b5-1 trading plan.

Summary

• On March 1, 2024, Timothy Sullivan, the Chief Financial Officer of Apellis Pharmaceuticals, exercised stock options to acquire 6,000 shares of common stock at a price of $10.03 per share.
• Sullivan then sold 4,000 shares at $62.86 per share and 2,000 shares at $63.95 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan established on December 1, 2023.
• Following these transactions, Sullivan directly owns 93,338 shares of Apellis Pharmaceuticals common stock.
• Sullivan also indirectly owns 56,232 shares through The Timothy E Sullivan Irrevocable Trust of 2023.
• He also holds options to purchase 261,903 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information. The market will likely view this as a standard transaction unless the volume is unusually high or low compared to historical insider trading activity.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the pharmaceutical sector like Regeneron, Novartis, and Roche, to utilize 10b5-1 trading plans.
• The size of the transaction (6,000 shares exercised, 6,000 shares sold) is relatively small compared to the total outstanding shares of Apellis Pharmaceuticals, suggesting it's unlikely to have a significant impact on the stock price.
• The exercise price of $10.03 is significantly lower than the sale prices of $62.86 and $63.95, indicating a substantial profit for the executive.
• Similar filings are regularly seen across the pharmaceutical industry, and the details of these filings are often scrutinized by investors for insights into executive sentiment and potential future company performance.

Key Dates